ProCAncer-I at the ECR 2024 in Vienna
February 29th 2024 at 08:00 CET
An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum: In Europe, prostate cancer (PC) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices lead to overdiagnosis and overtreatment, necessitating more effective tools for discriminating between aggressive and non-aggressive disease. The EU-funded ProCAncer-I project proposes to develop advanced artificial intelligence models to address unmet clinical needs: diagnosis, metastases detection and prediction of response to treatment. To achieve this, partners will generate a large interoperable repository of health images, and a scalable high-performance computing platform hosting the largest collection of PC Magnetic Resonance Images used for developing robust PC AI models. To ensure the rapid clinical implementation of the models developed, the project’s partners will robustly monitor performance, accuracy and reproducibility.
Welcome by Coordinating Team
We are very glad to lead a very ambitious and health-driven project that could end to alleviating and helping thousands of men to tackle prostate cancer in a more personalized way supporting a better quality of life
The Coordinating Team
Prof. Manolis Tsiknakis
Dr. Nikolaos Papanikolaou
Prof. Kostas Marias
Prof. Daniele Regge
The ProCAncer-I project is one of the founding projects of the FUTURE-AI.
FUTURE-AI is an international, multi-stakeholder initiative for defining and maintaining concrete guidelines that will facilitate the design, development, validation, and deployment of trustworthy AI solutions in medical imaging based on six guiding principles: Fairness, Universality, Traceability, Usability, Robustness, and Explainability.
Euros (Total Budget )
Grant Agreement Nr.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme
AI for Health Imaging